Education
About Us
Working with TipRanks
Follow Us
Chimerix (CMRX)
:CMRX
CMRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.75 - $8.53
Previous CloseN/A
Volume622.27K
Average Volume (3M)6.45M
Market Cap
$797.33M
Enterprise Value$183.64M
Total Cash (Recent Filing)$19.03M
Total Debt (Recent Filing)$1.67M
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
May 01, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding93,803,850
10 Day Avg. Volume1,548,454
30 Day Avg. Volume6,446,098
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4807.90
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit566.80
Enterprise Value/Ebitda-1.98
Forecast
1Y Price Target
$8.54Price Target Upside0.47% Upside
Rating ConsensusHold
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
AcquisitionThe acquisition agreement between Chimerix and Jazz Pharmaceuticals is expected to close in a timely manner, offering a stable financial outlook for Chimerix.
Drug PotentialDordaviprone, the lead drug in phase III trials, is seen as having the potential to become the standard of care with durable revenues into 2037.
Regulatory ApprovalThe FDA has accepted Chimerix's NDA with priority review status for dordaviprone, indicating a strong potential for approval.
Bears Say
Cash BurnThe company's estimated cash burn for the fiscal year is $98 million, suggesting a significant outflow of cash.
Financial PerformanceChimerix reported 4Q24 GAAP EPS of ($0.26) and non-GAAP EPS of ($0.25), both slightly below estimates.
Valuation ConcernsThe deal's valuation is lower than the biotech average, suggesting some skepticism about the company's prospects.
---
Ownership Overview
5.91% Insiders
6.65% Mutual Funds
30.53% Other Institutional Investors
52.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CMRX FAQ
What was Chimerix’s price range in the past 12 months?
Chimerix lowest stock price was $0.75 and its highest was $8.53 in the past 12 months.
What is Chimerix’s market cap?
Chimerix’s market cap is $797.33M.
When is Chimerix’s upcoming earnings report date?
Chimerix’s upcoming earnings report date is May 01, 2025 which is in 31 days.
How were Chimerix’s earnings last quarter?
Chimerix released its earnings results on Mar 21, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.26 by $0.01.
Is Chimerix overvalued?
According to Wall Street analysts Chimerix’s price is currently Undervalued.
Does Chimerix pay dividends?
Chimerix does not currently pay dividends.
What is Chimerix’s EPS estimate?
Chimerix’s EPS estimate is -0.26.
How many shares outstanding does Chimerix have?
Chimerix has 93,803,850 shares outstanding.
What happened to Chimerix’s price movement after its last earnings report?
Chimerix reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.26. Following the earnings report the stock price went up 0.354%.
Which hedge fund is a major shareholder of Chimerix?
Currently, no hedge funds are holding shares in CMRX
---
Chimerix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.54 (0.47% Upside)
$8.54 (0.47% Upside)
Blogger Sentiment
Bullish
CMRX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 17.1%
Last 30 Days ▼ 17.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
701.88%
12-Months-Change
Fundamentals
Return on Equity
-56.17%
Trailing 12-Months
Asset Growth
-31.38%
Trailing 12-Months
Company Description
Chimerix
Chimerix, Inc. (CMRX) is a biopharmaceutical company focused on the development and commercialization of novel antiviral therapeutics. Headquartered in Durham, North Carolina, Chimerix is committed to developing medicines that improve outcomes for patients facing serious diseases. The company's core product includes brincidofovir, an antiviral medication that is in development for various indications, including smallpox and other viral infections. Chimerix aims to address significant unmet medical needs with its innovative drug candidates by leveraging proprietary chemical libraries and expertise in antiviral drug development.
---
CMRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant progress in clinical studies and a strong financial position, despite the increased research expenses and net loss. The positive developments in the pipeline and financial management outweigh the challenges.Read More>---
CMRX Stock 12 Month Forecast
Average Price Target
$8.54
▲(0.47% Upside)
Technical Analysis
BioCryst
―
SIGA Technologies
―
Sarepta Therapeutics
―
Akebia Therapeutics
―
Vir Biotechnology
―
Best Analysts Covering CMRX
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
+131.44%
reiterated a buy rating 7 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of +131.44% per trade.
---